
microRNA could offer a safe target in atherosclerosis
The researcher demonstrateded that targeting of miR-206-3p with an experimental compound safely reversed the onset of atherosclerosis in a...

Researchers stop brain cell death in Alzheimer’s mice
The research team led by Prof. Bart De Strooper (VIB-KU Leuven/UK Dementia Research Institute), and Dr Sriram Balusu (VIB-KU Leuven) has finally...

Amyl Therapeutics bags €11m Series A extension
Amyl Therapeutics SA has secured €5m Series A extension from long-term investors Merieux Equity Partners and Noshaq, together with Mr Evren Ucok as a...

New detection method for protein degraders
The research team from MPI of Biochemistry and the University of Waterloo have developed a new way to detect those CRLs in the fleet that are...

Radiotherapy R&D partnership
French-US company Orano Med is developing Lead-212 (212Pb) Targeted Alpha Therapy, which combines the ability of biological molecules such as...

Takeover in ADC space: Abbvie snags ImmunoGen
AbbVie has become the latest big pharma company to target the hot antibody-drug conjugate market, acquiring ImmunoGen and its Elahere ADC for...

Memo Therapeutics AG raises CHF25m
The CHF25m Series C round of Schlieren-based Memo Therapeutics AG was led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital,...